Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Final Program


CRS Abstract Guide

Douglas Johns, PhD, FAHA

Clinical Pharmacology Lead
Merck Research Laboratories
Rahway, New Jersey, United States

Douglas Johns, PhD, FAHA joined Merck Translational Medicine in 2017 after working in Merck Cardiometabolic Discovery for 8 years. While in Discovery, Doug led the oral PCSK9 team and upon joining Translational Medicine, led the clinical development team for enlicitide/MK-0616. Doug is currently the clinical pharmacology lead for the enlicitide program, which is currently in Phase 3. Doug obtained a BS and MS in Biology from Baylor University, and a PhD in Physiology from the University of Michigan. Doug completed postdoctoral fellowships at the University of Michigan and Boston Medical Center.

Disclosure information not submitted.

Presentation(s):

Email Douglas